Cre8™ was just launched in Australia and New Zealand during the second ANZ CTO club meeting.
Professor Darren Walters and Dr. James Sapontis successfully implanted two Cre8™ stents during their live case. They commented on the high visibility and easy positioning of Cre8™ due to the platinum markers on the stent, and excellent deliverability. The result of the case was really good.
Cre8™ was also tested by physicians in hospitals in Australia, and the reception of the stent was excellent. Cre8™ has received great feedback on its deliverability, crossability, visibility, conformability and overall stent performance. In addition, Cre8™ is a stent that can provide additional benefit to diabetic patients due to its unique technologies. The Amphilimus™ formulation, which is a combination of Sirolimus and a Fatty acid, is especially effective on diabetic patients optimizing effectiveness, and Cre8™ being a polymer free stent together with our Bio Inducer Surface insures a very high safety for the patient.